'All-Comers' Trial Finds Increased Risk Of Thrombosis With Abbott's Absorb BVS Stent

Patients treated with Abbott Laboratories Inc.'s Absorb GT1 BVS bioabsorbable everolimus-eluting stent were 3.87 times as likely to develop a stent thrombosis as patients treated with Abbott's Xience everolimus-eluting metal stent within two years of implant in the Amsterdam Investigator-initiated Absorb Strategy All-comers (AIDA) trial.

The two-year results were published March 29 in the New England Journal of Medicine, just about a week after the two-year results of the ABSORB III trial showed Absorb was statistically inferior to Xience for the primary composite endpoint, as well as target-vessel myocardial infarction. The ABSORB III results, announced at the American College of Cardiology conference in Washington, DC, prompted the US FDA to send physicians a "Dear Doctor" letter highlighting the importance of proper patient selection and implant technique